US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Elicio Therapeutics

8.32

+0.71009.33%

Post-market: 8.320.00000.00%16:04 EST

Volume:115.82K

Turnover:934.70K

Market Cap:145.51M

PE:-2.69

High:8.34

Open:7.75

Low:7.51

Close:7.61

52wk High:12.62

52wk Low:4.60

Shares:17.49M

Float Shares:11.81M

Volume Ratio:0.63

T/O Rate:0.98%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.0883

EPS(LYR):-4.2529

ROE:-60013.19%

ROA:-79.40%

PB:38.13

PE(LYR):-1.96

Loading ...

Overview Company News Filings

Elicio Therapeutics reports inducement grants

Elicio Therapeutics Grants Inducement Stock Options to New Employees

Elicio Therapeutics Grants Stock Options to New Employees

Elicio Therapeutics Reports Phase 2 Trial Shows ELI-002 7P Induces Broad Immune Response Beyond mKRAS

Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond Mkras in Ongoing Phase 2 Amplify-7P Trial

THOMSON REUTERS

Elicio Therapeutics appoints Marc Wolfgang as CTO

Press Release: Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

H.C. Wainwright Sticks to Its Buy Rating for Elicio Therapeutics (ELTX)

JonesTrading Keeps Their Buy Rating on Elicio Therapeutics (ELTX)

Elicio Therapeutics Q3 EPS $(0.60) Misses $(0.55) Estimate

Elicio Therapeutics Q3 net loss narrows, cash runway extended

Elicio Therapeutics Reports Lower-Than-Projected Disease Progressions in Phase 2 AMPLIFY-7P Trial

Elicio Therapeutics Q3 Basic EPS USD -0.6

THOMSON REUTERS

Elicio Therapeutics Q3 Income From Operations USD -8.045 Million

THOMSON REUTERS

Elicio Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview

Elicio Therapeutics Reports Robust T Cell Responses in Phase 2 Trial of ELI-002 7P for KRAS-Mutant Pancreatic Cancer

Elicio Therapeutics Reports Robust, Cytolytic Mkras-Specific T Cell Responses Across Diverse Patient Hla in Ongoing Phase 2 Amplify-7P Trial of Eli-002 7P and New Eli-004 Preclinical Data at SITC

THOMSON REUTERS

Elicio Therapeutics Announces Late-Breaking Phase 2 Data on ELI-002 for Pancreatic Cancer at SITC 2025

Elicio Therapeutics Reports Robust T Cell Responses Across Diverse Hla Backgrounds in Ongoing Phase 2 Amplify-7P Trial

THOMSON REUTERS

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ELTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ELTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELTX\",,,,,undefined,":{"symbol":"ELTX","market":"US","secType":"STK","nameCN":"Elicio Therapeutics","latestPrice":8.32,"timestamp":1770411600000,"preClose":7.61,"halted":0,"volume":115821,"hourTrading":{"tag":"盘后","latestPrice":8.32,"preClose":8.32,"latestTime":"16:04 EST","volume":1,"amount":8.32,"timestamp":1770411863200,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.09329829172141918,"floatShares":11806099,"shares":17489516,"eps":-3.088325,"marketStatus":"Market Closed","change":0.71,"latestTime":"02-06 16:00:00 EST","open":7.75,"high":8.34,"low":7.505,"amount":934695.3304,"amplitude":0.109724,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.088325,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":7.61,"postHourTrading":{"tag":"盘后","latestPrice":8.32,"preClose":8.32,"latestTime":"16:04 EST","volume":1,"amount":8.32,"timestamp":1770411863200,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.628314,"impliedVol":1.6214,"impliedVolPercentile":0.799},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELTX\",,,,,undefined,":{"symbol":"ELTX","floatShares":11806099,"roa":"-79.40%","roe":"-60013.19%","lyrEps":-4.25289,"volumeRatio":0.628314,"shares":17489516,"dividePrice":0,"high":8.34,"amplitude":0.109724,"preClose":7.61,"low":7.505,"week52Low":4.6,"pbRate":"38.13","week52High":12.62,"institutionHeld":0,"latestPrice":8.32,"eps":-3.088325,"divideRate":0,"volume":115821,"delay":0,"ttmEps":-3.088325,"open":7.75,"prevYearClose":7.96,"prevWeekClose":7.6,"prevMonthClose":7.6,"prevQuarterClose":7.96},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ELTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"ELTX","fiscalQuarterEnding":"2025/09","expectedEps":-0.62,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.6},{"market":"US","date":"2025-08-07","symbol":"ELTX","fiscalQuarterEnding":"2025/06","expectedEps":-0.69,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-05-13","symbol":"ELTX","fiscalQuarterEnding":"2025/03","expectedEps":-0.67,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-0.87},{"market":"US","date":"2025-03-31","symbol":"ELTX","fiscalQuarterEnding":"2024/12","expectedEps":-0.94,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":-1.02},{"market":"US","date":"2024-11-13","symbol":"ELTX","fiscalQuarterEnding":"2024/09","expectedEps":-0.81,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-1.39}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ELTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ELTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1743570000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ELTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ELTX","date":"2026-02-05","current":-2.648685,"percent":0.20418,"low":-9.235249,"twenty":-3.002032,"median":-2.121187,"eighty":-1.328561,"high":-0.963611,"avg":-2.233373,"sd":0.986091,"marketCap":137179228},"quantilePoints":[{"date":"2023-06-09","current":-9.235249,"twenty":-9.235249,"median":-9.19865,"eighty":-8.861936,"marketCap":260505032},{"date":"2023-06-16","current":-4.797096,"twenty":-9.19133,"median":-5.471097,"eighty":-5.286091,"marketCap":135315000},{"date":"2023-06-23","current":-3.669177,"twenty":-9.011993,"median":-5.35246,"eighty":-4.343178,"marketCap":103499000},{"date":"2023-06-30","current":-3.232452,"twenty":-8.711878,"median":-5.281964,"eighty":-3.931212,"marketCap":91180000},{"date":"2023-07-07","current":-3.782657,"twenty":-7.82363,"median":-4.797096,"eighty":-3.594899,"marketCap":106700000},{"date":"2023-07-14","current":-3.799851,"twenty":-5.457342,"median":-4.009616,"eighty":-3.669177,"marketCap":107185000},{"date":"2023-07-21","current":-3.868626,"twenty":-5.416077,"median":-3.868626,"eighty":-3.616907,"marketCap":109125000},{"date":"2023-07-28","current":-3.026831,"twenty":-5.342487,"median":-3.782657,"eighty":-3.314983,"marketCap":85379914},{"date":"2023-08-04","current":-2.958445,"twenty":-5.286091,"median":-3.758585,"eighty":-2.99472,"marketCap":83450898},{"date":"2023-08-11","current":-2.973312,"twenty":-5.075638,"median":-3.643386,"eighty":-2.969744,"marketCap":83870250},{"date":"2023-08-18","current":-2.842099,"twenty":-4.570137,"median":-3.57633,"eighty":-2.953093,"marketCap":83656289},{"date":"2023-08-25","current":-2.726636,"twenty":-4.18018,"median":-3.222136,"eighty":-2.868421,"marketCap":79553028},{"date":"2023-09-01","current":-2.370739,"twenty":-4.067388,"median":-3.000071,"eighty":-2.849368,"marketCap":69169264},{"date":"2023-09-07","current":-2.433882,"twenty":-3.951844,"median":-2.973312,"eighty":-2.844375,"marketCap":71011545},{"date":"2023-09-15","current":-2.413791,"twenty":-3.886508,"median":-2.973312,"eighty":-2.761879,"marketCap":70425365},{"date":"2023-09-22","current":-2.293245,"twenty":-3.841116,"median":-2.967365,"eighty":-2.647421,"marketCap":66908283},{"date":"2023-09-29","current":-2.413791,"twenty":-3.792973,"median":-2.953985,"eighty":-2.537207,"marketCap":70425365},{"date":"2023-10-04","current":-2.276024,"twenty":-3.782657,"median":-2.940605,"eighty":-2.474064,"marketCap":66405843},{"date":"2023-10-10","current":-2.098075,"twenty":-3.781281,"median":-2.875192,"eighty":-2.428715,"marketCap":61213961},{"date":"2023-10-19","current":-2.009101,"twenty":-3.779218,"median":-2.868708,"eighty":-2.413791,"marketCap":58618021},{"date":"2023-10-27","current":-1.922996,"twenty":-3.775091,"median":-2.867273,"eighty":-2.413791,"marketCap":56105820},{"date":"2023-11-03","current":-1.871334,"twenty":-3.740703,"median":-2.849368,"eighty":-2.290949,"marketCap":54598499},{"date":"2023-11-10","current":-1.690515,"twenty":-3.669177,"median":-2.844944,"eighty":-2.243878,"marketCap":49322877},{"date":"2023-11-17","current":-1.533738,"twenty":-3.658861,"median":-2.768921,"eighty":-2.084298,"marketCap":50453368},{"date":"2023-11-24","current":-1.527374,"twenty":-3.617595,"median":-2.739552,"eighty":-1.974659,"marketCap":50244018},{"date":"2023-12-01","current":-1.565558,"twenty":-3.614157,"median":-2.617571,"eighty":-1.90147,"marketCap":51500118},{"date":"2023-12-08","current":-1.48919,"twenty":-3.583895,"median":-2.583129,"eighty":-1.87076,"marketCap":48987917},{"date":"2023-12-15","current":-1.540102,"twenty":-3.452534,"median":-2.531467,"eighty":-1.708711,"marketCap":50662718},{"date":"2023-12-22","current":-1.476462,"twenty":-3.314983,"median":-2.474064,"eighty":-1.60527,"marketCap":48569217},{"date":"2023-12-29","current":-2.102685,"twenty":-3.232452,"median":-2.429577,"eighty":-1.641927,"marketCap":69169264},{"date":"2024-01-05","current":-2.03949,"twenty":-3.220072,"median":-2.413791,"eighty":-1.611379,"marketCap":67090423},{"date":"2024-01-12","current":-1.576818,"twenty":-3.100826,"median":-2.392265,"eighty":-1.585578,"marketCap":51870515},{"date":"2024-01-19","current":-1.427896,"twenty":-3.005423,"median":-2.30616,"eighty":-1.564031,"marketCap":46971633},{"date":"2024-01-26","current":-1.124213,"twenty":-2.973312,"median":-2.283466,"eighty":-1.540772,"marketCap":36981756},{"date":"2024-02-02","current":-1.314015,"twenty":-2.973312,"median":-2.260238,"eighty":-1.528392,"marketCap":43225429},{"date":"2024-02-09","current":-1.226414,"twenty":-2.973312,"median":-2.227231,"eighty":-1.508027,"marketCap":40343734},{"date":"2024-02-16","current":-1.220574,"twenty":-2.970933,"median":-2.10038,"eighty":-1.496317,"marketCap":40151621},{"date":"2024-02-23","current":-1.170933,"twenty":-2.967365,"median":-2.077039,"eighty":-1.484607,"marketCap":38518660},{"date":"2024-03-01","current":-1.185534,"twenty":-2.965581,"median":-2.037802,"eighty":-1.427936,"marketCap":38998943},{"date":"2024-03-08","current":-1.305255,"twenty":-2.958445,"median":-1.951697,"eighty":-1.350807,"marketCap":42937259},{"date":"2024-03-15","current":-1.530098,"twenty":-2.956661,"median":-1.917256,"eighty":-1.360152,"marketCap":50333611},{"date":"2024-03-22","current":-1.927222,"twenty":-2.947741,"median":-1.909363,"eighty":-1.380707,"marketCap":63397296},{"date":"2024-03-28","current":-2.178345,"twenty":-2.940605,"median":-1.925109,"eighty":-1.425549,"marketCap":71658156},{"date":"2024-04-05","current":-2.18389,"twenty":-2.875192,"median":-1.928736,"eighty":-1.427896,"marketCap":76862025},{"date":"2024-04-12","current":-2.872164,"twenty":-2.872164,"median":-2.000282,"eighty":-1.428095,"marketCap":101085828},{"date":"2024-04-19","current":-2.390082,"twenty":-2.870144,"median":-2.037802,"eighty":-1.436656,"marketCap":84118945},{"date":"2024-04-26","current":-2.64274,"twenty":-2.867273,"median":-2.070475,"eighty":-1.460017,"marketCap":93011227},{"date":"2024-05-03","current":-2.613699,"twenty":-2.860548,"median":-2.080854,"eighty":-1.476462,"marketCap":91989126},{"date":"2024-05-10","current":-2.758904,"twenty":-2.852923,"median":-2.121507,"eighty":-1.483377,"marketCap":97099633},{"date":"2024-05-17","current":-2.458726,"twenty":-2.860548,"median":-2.154849,"eighty":-1.484098,"marketCap":95873111},{"date":"2024-05-24","current":-2.3198,"twenty":-2.852923,"median":-2.20556,"eighty":-1.486644,"marketCap":90455973},{"date":"2024-05-31","current":-1.968554,"twenty":-2.850079,"median":-2.181118,"eighty":-1.488681,"marketCap":76759815},{"date":"2024-06-07","current":-2.125179,"twenty":-2.849368,"median":-2.152608,"eighty":-1.489212,"marketCap":82867106},{"date":"2024-06-14","current":-2.233016,"twenty":-2.846714,"median":-2.152608,"eighty":-1.492255,"marketCap":87071996},{"date":"2024-06-21","current":-1.741174,"twenty":-2.844944,"median":-2.140329,"eighty":-1.496317,"marketCap":67893594},{"date":"2024-06-28","current":-1.812189,"twenty":-2.844944,"median":-2.140329,"eighty":-1.498354,"marketCap":70662668},{"date":"2024-07-05","current":-0.967903,"twenty":-2.843237,"median":-2.110101,"eighty":-1.488172,"marketCap":37741454},{"date":"2024-07-12","current":-1.249432,"twenty":-2.834001,"median":-2.100781,"eighty":-1.469884,"marketCap":48719089},{"date":"2024-07-15","current":-1.260464,"twenty":-2.831302,"median":-2.098877,"eighty":-1.455345,"marketCap":49149280},{"date":"2024-08-02","current":-1.401267,"twenty":-2.828603,"median":-2.098877,"eighty":-1.436656,"marketCap":54639616},{"date":"2024-08-09","current":-1.290931,"twenty":-2.802466,"median":-2.080854,"eighty":-1.401267,"marketCap":50337284},{"date":"2024-08-16","current":-1.201045,"twenty":-2.796658,"median":-2.072003,"eighty":-1.349055,"marketCap":46438413},{"date":"2024-08-23","current":-1.241178,"twenty":-2.769689,"median":-2.062918,"eighty":-1.296495,"marketCap":47990130},{"date":"2024-08-30","current":-1.113164,"twenty":-2.768153,"median":-2.038646,"eighty":-1.281895,"marketCap":43040476},{"date":"2024-09-06","current":-1.110381,"twenty":-2.760754,"median":-2.011962,"eighty":-1.261256,"marketCap":42932874},{"date":"2024-09-13","current":-1.132616,"twenty":-2.753755,"median":-1.991463,"eighty":-1.24953,"marketCap":43792608},{"date":"2024-09-20","current":-1.430415,"twenty":-2.736707,"median":-1.971607,"eighty":-1.23844,"marketCap":55307011},{"date":"2024-09-27","current":-1.355277,"twenty":-2.727862,"median":-1.927222,"eighty":-1.247781,"marketCap":52401779},{"date":"2024-10-04","current":-1.35806,"twenty":-2.717602,"median":-1.920126,"eighty":-1.24953,"marketCap":52509380},{"date":"2024-10-11","current":-1.333014,"twenty":-2.703726,"median":-1.89225,"eighty":-1.251663,"marketCap":51540970},{"date":"2024-10-18","current":-1.327448,"twenty":-2.69392,"median":-1.871334,"eighty":-1.251663,"marketCap":51325767},{"date":"2024-10-25","current":-1.330231,"twenty":-2.68748,"median":-1.868821,"eighty":-1.256738,"marketCap":51433368},{"date":"2024-10-31","current":-1.15769,"twenty":-2.682816,"median":-1.860061,"eighty":-1.249543,"marketCap":44762095},{"date":"2024-11-08","current":-1.282921,"twenty":-2.678751,"median":-1.809791,"eighty":-1.251136,"marketCap":49604148},{"date":"2024-11-15","current":-1.251898,"twenty":-2.674104,"median":-1.720841,"eighty":-1.252073,"marketCap":58642648},{"date":"2024-11-22","current":-1.176095,"twenty":-2.654356,"median":-1.667384,"eighty":-1.249488,"marketCap":55091809},{"date":"2024-11-29","current":-1.171024,"twenty":-2.64274,"median":-1.629813,"eighty":-1.227353,"marketCap":54854273},{"date":"2024-12-06","current":-1.106606,"twenty":-2.639384,"median":-1.600178,"eighty":-1.22448,"marketCap":51836749},{"date":"2024-12-13","current":-1.148018,"twenty":-2.631897,"median":-1.571188,"eighty":-1.222594,"marketCap":53776586},{"date":"2024-12-20","current":-1.167573,"twenty":-2.62396,"median":-1.563013,"eighty":-1.217317,"marketCap":54692620},{"date":"2024-12-27","current":-1.166423,"twenty":-2.616797,"median":-1.547739,"eighty":-1.213926,"marketCap":54638735},{"date":"2025-01-03","current":-1.182527,"twenty":-2.613699,"median":-1.540102,"eighty":-1.211814,"marketCap":55393116},{"date":"2025-01-10","current":-1.304461,"twenty":-2.611376,"median":-1.530098,"eighty":-1.211814,"marketCap":61104858},{"date":"2025-01-17","current":-1.48161,"twenty":-2.609328,"median":-1.528647,"eighty":-1.213041,"marketCap":69403049},{"date":"2025-01-24","current":-1.656458,"twenty":-2.608318,"median":-1.528647,"eighty":-1.213574,"marketCap":77593471},{"date":"2025-01-31","current":-2.167199,"twenty":-2.60789,"median":-1.530098,"eighty":-1.21433,"marketCap":101518124},{"date":"2025-02-07","current":-2.162598,"twenty":-2.593884,"median":-1.54094,"eighty":-1.214734,"marketCap":101302587},{"date":"2025-02-14","current":-1.769189,"twenty":-2.583696,"median":-1.557921,"eighty":-1.214981,"marketCap":82874137},{"date":"2025-02-21","current":-1.863515,"twenty":-2.577932,"median":-1.565558,"eighty":-1.217317,"marketCap":87292655},{"date":"2025-02-28","current":-1.902626,"twenty":-2.570137,"median":-1.584118,"eighty":-1.220574,"marketCap":89124723},{"date":"2025-03-07","current":-1.833607,"twenty":-2.564329,"median":-1.603098,"eighty":-1.220574,"marketCap":85891661},{"date":"2025-03-14","current":-2.672649,"twenty":-2.570137,"median":-1.649192,"eighty":-1.221023,"marketCap":125194918},{"date":"2025-03-21","current":-2.747078,"twenty":-2.60789,"median":-1.669929,"eighty":-1.222594,"marketCap":128681358},{"date":"2025-03-28","current":-2.594838,"twenty":-2.612537,"median":-1.719708,"eighty":-1.224155,"marketCap":121550002},{"date":"2025-04-04","current":-1.679468,"twenty":-2.612537,"median":-1.718575,"eighty":-1.22448,"marketCap":87161019},{"date":"2025-04-11","current":-1.557114,"twenty":-2.610061,"median":-1.684991,"eighty":-1.225254,"marketCap":80811079},{"date":"2025-04-17","current":-1.492618,"twenty":-2.608747,"median":-1.667384,"eighty":-1.226414,"marketCap":77463875},{"date":"2025-04-25","current":-1.557114,"twenty":-2.60789,"median":-1.641927,"eighty":-1.226584,"marketCap":80811079},{"date":"2025-05-02","current":-1.541757,"twenty":-2.60528,"median":-1.62119,"eighty":-1.227308,"marketCap":80014126},{"date":"2025-05-09","current":-1.710675,"twenty":-2.59278,"median":-1.624681,"eighty":-1.230226,"marketCap":88780614},{"date":"2025-05-16","current":-1.653585,"twenty":-2.584263,"median":-1.647756,"eighty":-1.242829,"marketCap":84795847},{"date":"2025-05-23","current":-1.600745,"twenty":-2.580531,"median":-1.656458,"eighty":-1.249451,"marketCap":82086205},{"date":"2025-05-30","current":-2.337537,"twenty":-2.570137,"median":-1.661535,"eighty":-1.249526,"marketCap":119868907},{"date":"2025-06-06","current":-2.328187,"twenty":-2.570137,"median":-1.667973,"eighty":-1.249555,"marketCap":119389431},{"date":"2025-06-13","current":-2.499606,"twenty":-2.555617,"median":-1.681559,"eighty":-1.251898,"marketCap":128179818},{"date":"2025-06-20","current":-2.480906,"twenty":-2.548647,"median":-1.689176,"eighty":-1.252132,"marketCap":127220867},{"date":"2025-06-27","current":-2.462206,"twenty":-2.546034,"median":-1.702427,"eighty":-1.256738,"marketCap":126261915},{"date":"2025-07-03","current":-2.465323,"twenty":-2.537207,"median":-1.714625,"eighty":-1.258423,"marketCap":126421741},{"date":"2025-07-11","current":-2.577524,"twenty":-2.561425,"median":-1.730079,"eighty":-1.259794,"marketCap":132175448},{"date":"2025-07-18","current":-2.898546,"twenty":-2.579766,"median":-1.757979,"eighty":-1.261058,"marketCap":148637445},{"date":"2025-07-25","current":-3.057499,"twenty":-2.600059,"median":-1.764061,"eighty":-1.263206,"marketCap":156788531},{"date":"2025-08-01","current":-3.057499,"twenty":-2.611957,"median":-1.792196,"eighty":-1.270493,"marketCap":156788531},{"date":"2025-08-08","current":-2.826862,"twenty":-2.625853,"median":-1.812189,"eighty":-1.274572,"marketCap":144961465},{"date":"2025-08-15","current":-2.971121,"twenty":-2.638357,"median":-1.82441,"eighty":-1.276242,"marketCap":162258860},{"date":"2025-08-22","current":-3.41649,"twenty":-2.660123,"median":-1.836892,"eighty":-1.279025,"marketCap":186581365},{"date":"2025-08-29","current":-3.090683,"twenty":-2.678751,"median":-1.856037,"eighty":-1.280138,"marketCap":168788391},{"date":"2025-09-05","current":-3.243125,"twenty":-2.691143,"median":-1.861215,"eighty":-1.280841,"marketCap":177113544},{"date":"2025-09-12","current":-3.461326,"twenty":-2.704217,"median":-1.868463,"eighty":-1.282305,"marketCap":189029939},{"date":"2025-09-19","current":-3.426952,"twenty":-2.741354,"median":-1.870693,"eighty":-1.282921,"marketCap":187152699},{"date":"2025-09-26","current":-3.243125,"twenty":-2.769075,"median":-1.877319,"eighty":-1.282921,"marketCap":177113544},{"date":"2025-10-03","current":-3.308884,"twenty":-2.807845,"median":-1.880771,"eighty":-1.283679,"marketCap":180704787},{"date":"2025-10-10","current":-3.302906,"twenty":-2.827907,"median":-1.893424,"eighty":-1.284815,"marketCap":180378310},{"date":"2025-10-17","current":-3.004001,"twenty":-2.847185,"median":-1.902048,"eighty":-1.285226,"marketCap":164054481},{"date":"2025-10-24","current":-2.839603,"twenty":-2.847185,"median":-1.911829,"eighty":-1.285928,"marketCap":155076375},{"date":"2025-10-31","current":-2.764876,"twenty":-2.849368,"median":-1.920126,"eighty":-1.286056,"marketCap":150995418},{"date":"2025-11-07","current":-2.711073,"twenty":-2.849092,"median":-1.927222,"eighty":-1.288006,"marketCap":148057129},{"date":"2025-11-14","current":-2.723029,"twenty":-2.847185,"median":-1.960142,"eighty":-1.291742,"marketCap":148710082},{"date":"2025-11-21","current":-3.044807,"twenty":-2.852183,"median":-1.968554,"eighty":-1.293396,"marketCap":139625737},{"date":"2025-11-28","current":-3.566883,"twenty":-2.866671,"median":-1.979039,"eighty":-1.294541,"marketCap":163566570},{"date":"2025-12-05","current":-3.172468,"twenty":-2.874818,"median":-2.003244,"eighty":-1.298088,"marketCap":145479882},{"date":"2025-12-12","current":-3.189617,"twenty":-2.895724,"median":-2.026861,"eighty":-1.30462,"marketCap":146266260},{"date":"2025-12-19","current":-3.044807,"twenty":-2.909766,"median":-2.045829,"eighty":-1.306911,"marketCap":139625737},{"date":"2025-12-26","current":-3.121023,"twenty":-2.940605,"median":-2.061171,"eighty":-1.313533,"marketCap":143120749},{"date":"2026-01-02","current":-3.033375,"twenty":-2.951309,"median":-2.069254,"eighty":-1.313919,"marketCap":139101485},{"date":"2026-01-09","current":-3.140077,"twenty":-2.967365,"median":-2.073224,"eighty":-1.319745,"marketCap":143994502},{"date":"2026-01-16","current":-2.976214,"twenty":-2.971559,"median":-2.091032,"eighty":-1.321741,"marketCap":136480226},{"date":"2026-01-23","current":-3.052429,"twenty":-2.973312,"median":-2.098877,"eighty":-1.323552,"marketCap":139975238},{"date":"2026-01-30","current":-3.079104,"twenty":-2.996791,"median":-2.104138,"eighty":-1.326335,"marketCap":141198492},{"date":"2026-02-05","current":-2.991457,"twenty":-3.002032,"median":-2.121187,"eighty":-1.328561,"marketCap":137179228}],"updateTime":1770408844320},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ELTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2603967639","title":"Elicio Therapeutics reports inducement grants","url":"https://stock-news.laohu8.com/highlight/detail?id=2603967639","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603967639?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:12","pubTimestamp":1768569141,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics (ELTX) announced that on January 15, Elicio granted an aggregate of 22,400 inducement stock options to two new employees, as an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/elicio-therapeutics-reports-inducement-grants-thefly-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/elicio-therapeutics-reports-inducement-grants-thefly-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ELTX","BK4007"],"gpt_icon":0},{"id":"2603399685","title":"Elicio Therapeutics Grants Inducement Stock Options to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2603399685","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603399685?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:00","pubTimestamp":1768568420,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics Inc. has granted an aggregate of 22,400 inducement stock options to two new employees. Each option allows for the purchase of Elicio common stock at $7.81 per share, the closing price on January 15, 2026. The stock options vest over four years, with 25 percent vesting on the first anniversary of each employee’s start date and the remainder vesting monthly thereafter, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL355Q1R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4139","ELTX","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4112","SG9999014013.SGD","BK4007","LU2095319765.USD","BK4588","SG9999014021.USD","LU2210150020.SGD","SG9999014039.USD","LU2210149790.SGD","BK4585","SG9999014005.SGD","LU0314104364.USD"],"gpt_icon":0},{"id":"2591769984","title":"Elicio Therapeutics Grants Stock Options to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2591769984","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591769984?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:00","pubTimestamp":1765890016,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics Inc. has granted a total of 157,193 inducement stock options to three new employees. Each option allows for the purchase of Elicio common stock at $8.52 per share, the closing price on December 15, 2025. The options vest over four years, with 25 percent vesting after the first year and the remainder vesting monthly thereafter, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 16, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDLb86TFd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4139","ELTX","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4112","SG9999014013.SGD","BK4007","LU2095319765.USD","BK4588","SG9999014021.USD","LU2210150020.SGD","SG9999014039.USD","LU2210149790.SGD","BK4585","SG9999014005.SGD","LU0314104364.USD"],"gpt_icon":0},{"id":"2590017515","title":"Elicio Therapeutics Reports Phase 2 Trial Shows ELI-002 7P Induces Broad Immune Response Beyond mKRAS","url":"https://stock-news.laohu8.com/highlight/detail?id=2590017515","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590017515?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458035,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics Inc. announced new interim results from its ongoing Phase 2 AMPLIFY-7P trial evaluating ELI-002 7P, an off-the-shelf targeted immunotherapy for cancer. Analysis of a subset of patients demonstrated that 87%  showed induction of T cell responses to tumor neoantigens beyond the targeted mKRAS. This antigen spreading indicates that ELI-002 7P may broaden immune responses to include personalized tumor antigens not present in the original therapy. The company stated that these findings are consistent with previous Phase 1 data. The results have already been presented in the company's recent announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL9s5Kqp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014013.SGD","LU2210150020.SGD","ELTX","SG9999014039.USD","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014021.USD","BK4112","BK4588","SG9999014005.SGD","IE00B64PRP62.GBP","LU0314104364.USD","BK4139","BK4007","NDAQ","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2590082515","title":"Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond Mkras in Ongoing Phase 2 Amplify-7P Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590082515","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590082515?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA1NXCT8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ELTX","BK4007"],"gpt_icon":0},{"id":"2584941136","title":"Elicio Therapeutics appoints Marc Wolfgang as CTO","url":"https://stock-news.laohu8.com/highlight/detail?id=2584941136","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584941136?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:10","pubTimestamp":1763557859,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics (ELTX) announced the appointment of Marc Wolfgang, M.S. as Chief Technology Officer. He most recently served as Senior Vice Pre...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/elicio-therapeutics-appoints-marc-wolfgang-as-cto-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/elicio-therapeutics-appoints-marc-wolfgang-as-cto-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ELTX","LU1066051811.HKD","LU1066051498.USD","LU1066053197.SGD","BK4160","BK4139","CTO","LU1066051225.USD"],"gpt_icon":0},{"id":"2584949785","title":"Press Release: Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584949785","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584949785?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:00","pubTimestamp":1763557200,"startTime":"0","endTime":"0","summary":"BOSTON, Nov. 19, 2025  -- Elicio Therapeutics, Inc. , a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Marc J. Wolfgang, M.S. as Chief Technology Officer .\"Marc is an exceptional CMC strategy and operations leader with deep experience guiding innovative therapeutic platforms from early development through commercial readiness,\" said Robert T. Connelly, President and Chief Executive Officer of Elicio. \"As we continue preparing for potential late-stage development and commercial-scale execution of ELI-002 7P and advancing our other pipeline assets, Marc's expertise across cell therapy, RNA-based medicines, and other complex modalities aligns perfectly with our strategic priorities. We are thrilled to welcome him to the executive team at this important moment for Elicio.\"","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","LU2237443382.USD","CMC","LU2746668461.USD","IE00BKVL7J92.USD","IE00BFXG1179.USD","LU2237443622.USD","LU0170899867.USD","LU0149725797.USD","LU1363072403.SGD","IE00BHPRN162.USD","IE00BZ1G4Q59.USD","LU2237443895.HKD","LU2237443978.SGD","IE00B1BXHZ80.USD","BK4007","BK4139","ELTX","LU2746668974.SGD","LU0971096721.USD","LU2237443465.HKD","LU2237443549.SGD","LU0267386448.USD","LU0882574139.USD"],"gpt_icon":0},{"id":"2584943567","title":"H.C. Wainwright Sticks to Its Buy Rating for Elicio Therapeutics (ELTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584943567","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584943567?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:37","pubTimestamp":1763552252,"startTime":"0","endTime":"0","summary":"In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Elicio Therapeutics, with a price target of $13.00. Accord...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-elicio-therapeutics-eltx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-elicio-therapeutics-eltx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELTX"],"gpt_icon":0},{"id":"2583509565","title":"JonesTrading Keeps Their Buy Rating on Elicio Therapeutics (ELTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583509565","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583509565?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:16","pubTimestamp":1763126160,"startTime":"0","endTime":"0","summary":"In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Elicio Therapeutics, with a price target of $18.00. According t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-keeps-their-buy-rating-on-elicio-therapeutics-eltx-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-keeps-their-buy-rating-on-elicio-therapeutics-eltx-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELTX"],"gpt_icon":0},{"id":"2583512269","title":"Elicio Therapeutics Q3 EPS $(0.60) Misses $(0.55) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583512269","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583512269?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:32","pubTimestamp":1763069579,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics Q3 EPS $(0.60) Misses $(0.55) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48851419/elicio-therapeutics-q3-eps-0-60-misses-0-55-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Elicio Therapeutics Q3 EPS $(0.60) Misses $(0.55) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX"],"gpt_icon":0},{"id":"2583051498","title":"Elicio Therapeutics Q3 net loss narrows, cash runway extended","url":"https://stock-news.laohu8.com/highlight/detail?id=2583051498","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583051498?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:10","pubTimestamp":1763068240,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics Q3 net loss narrows, cash runway extendedOverviewElicio's Q3 2025 net loss narrows to $10.1 mln from $18.8 mln in Q3 2024Company raised $11.1 mln since Q3 2025, extending cash runw","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP16U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX","BK4007","BK4139"],"gpt_icon":0},{"id":"2583111215","title":"Elicio Therapeutics Reports Lower-Than-Projected Disease Progressions in Phase 2 AMPLIFY-7P Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2583111215","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583111215?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:01","pubTimestamp":1763067702,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL4XyBrk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4585","ELTX","LU2210149790.SGD","LU2095319765.USD","BK4139","BK4588","BK4007","LU2210150020.SGD","BK4112","LU0314104364.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ"],"gpt_icon":0},{"id":"2583119175","title":"Elicio Therapeutics Q3 Basic EPS USD -0.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2583119175","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583119175?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:01","pubTimestamp":1763067661,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX5E4AB0:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ELTX","BK4007"],"gpt_icon":0},{"id":"2583116165","title":"Elicio Therapeutics Q3 Income From Operations USD -8.045 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583116165","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583116165?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:01","pubTimestamp":1763067661,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX5E4AB0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ELTX","BK4007"],"gpt_icon":0},{"id":"2581501837","title":"Elicio Therapeutics Inc  expected to post a loss of 55 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581501837","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581501837?lang=en_us&edition=fundamental","pubTime":"2025-11-08 07:13","pubTimestamp":1762557184,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics Inc  expected to post a loss of55cents a share - Earnings Preview Elicio Therapeutics Inc ELTX.OQ ELTX.O is expected to  show no change in quarterly revenue when it reports  result","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ32O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX","BK4007","BK4139"],"gpt_icon":0},{"id":"2581886305","title":"Elicio Therapeutics Reports Robust T Cell Responses in Phase 2 Trial of ELI-002 7P for KRAS-Mutant Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2581886305","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581886305?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:00","pubTimestamp":1762524044,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics Inc. has announced updated immunogenicity results from its ongoing Phase 2 AMPLIFY-7P trial of ELI-002 7P, a lymph node-targeted amphiphile therapeutic cancer vaccine for patients with KRAS-mutated pancreatic ductal adenocarcinoma. According to the company, ELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients , with robust immune responses observed across all seven mKRAS antigens. More than 80% of patients responded to each individual KRAS mutation, and 88% generated responses to their own tumor-specific mutation. Cytotoxic mKRAS-specific T cell responses were induced in 86.8% of patients , with both CD8+ and CD4+ T cells detected in 75% of cases. The company remains blinded to the clinical efficacy outcomes of the trial. These data will be presented at the Society for Immunotherapy of Cancer  2025 Annual Meeting, scheduled for November 7-8, 2025, in National Harbor, MD. Additionally, preclinical data on ELI-004, an intra-tumoral immunothe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL1CcLKq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210149790.SGD","BK4139","BK4588","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4585","NDAQ","LU2210150020.SGD","LU2095319765.USD","BK4007","ELTX","IE00B64PRP62.GBP","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2581886813","title":"Elicio Therapeutics Reports Robust, Cytolytic Mkras-Specific T Cell Responses Across Diverse Patient Hla in Ongoing Phase 2 Amplify-7P Trial of Eli-002 7P and New Eli-004 Preclinical Data at SITC","url":"https://stock-news.laohu8.com/highlight/detail?id=2581886813","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581886813?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:00","pubTimestamp":1762524006,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUA3DQP6J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELTX","BK4139"],"gpt_icon":0},{"id":"2580213595","title":"Elicio Therapeutics Announces Late-Breaking Phase 2 Data on ELI-002 for Pancreatic Cancer at SITC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580213595","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580213595?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:02","pubTimestamp":1762174945,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics Inc. has announced that it will present new clinical and preclinical data at the Society for Immunotherapy of Cancer's  40th Anniversary Annual Meeting, scheduled to take place November 5-9, 2025, in National Harbor, Maryland. The company will share a late-breaking poster highlighting new immunogenicity data from its ongoing Phase 2 AMPLIFY-7P trial of ELI-002 in patients with mKRAS-driven pancreatic cancer. Additionally, preclinical data from ELI-004 for the treatment of advanced solid tumors will be presented in a separate poster session. The results are set to be presented at the upcoming meeting and have not yet been disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDLDZJRP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","ELTX","BK4585","LU2095319765.USD","LU2210150020.SGD","LU0314104364.USD","BK4588","LU2210149790.SGD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4007","IE00B3QW5Z07.USD","BK4112","IE00BGHQF748.EUR","BK4139"],"gpt_icon":0},{"id":"2578456866","title":"Elicio Therapeutics Reports Robust T Cell Responses Across Diverse Hla Backgrounds in Ongoing Phase 2 Amplify-7P Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2578456866","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578456866?lang=en_us&edition=fundamental","pubTime":"2025-10-27 20:00","pubTimestamp":1761566404,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nTUABTS33R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ELTX","BK4007"],"gpt_icon":0},{"id":"2578645722","title":"Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2578645722","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578645722?lang=en_us&edition=fundamental","pubTime":"2025-10-27 20:00","pubTimestamp":1761566400,"startTime":"0","endTime":"0","summary":"ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use among a diverse patient populationPatients treated with ELI-002 7P ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/27/3174537/0/en/Elicio-Therapeutics-Reports-Robust-T-cell-Responses-Across-Diverse-HLA-backgrounds-in-Ongoing-Phase-2-AMPLIFY-7P-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ELTX"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":39,"code":"91000000","status":"200"}]}}